What is the four-phase gap assessment process for QMSR compliance?
Answered at 20:10 in #474: Behind the QMSR Audits: The Top 5 FDA Citations & Risk Management Pitfalls · Global Medical Device Podcast powered by Greenlight Guru
What is the four-phase gap assessment process for QMSR compliance?
The first phase examines risk documentation across product realization and whether the risk file is live and receiving recent complaint data. The second phase checks interfaces between QMS elements—complaints making it to risk, non-conformances to CAPAs, service records to feedback, and returns to complaints. The third phase covers FDA-specific overlays like UDI, device tracking, reporting, corrections and removals. The fourth phase reviews records that just became visible to FDA, such as management reviews, internal audits, and supplier audits, which were previously exempt but now are regulatory evidence.
Full answer and detailsRead the whole answer, key facts and every other question from this episode
In short
The first phase examines risk documentation across product realization and whether the risk file is live and receiving recent complaint data.
Nikhil Mangali, Vice President of Quality at Capstone Medical · #474: Behind the QMSR Audits: The Top 5 FDA Citations & Risk Management Pitfalls · Global Medical Device Podcast powered by Greenlight Guru · answer at 20:10
Key takeaways
- The first phase examines risk documentation across product realization and whether the risk file is live and receiving recent complaint data.
Quote to remember
“Your own risk documentation tells you that. Your own file is now the navigation instrument for an investigator.”
— Nikhil Mangali
The full answer · about 4 min
The first phase examines risk documentation across product realization and whether the risk file is live and receiving recent complaint data. The second phase checks interfaces between QMS elements—complaints making it to risk, non-conformances to CAPAs, service records to feedback, and returns to complaints. The third phase covers FDA-specific overlays like UDI, device tracking, reporting, corrections and removals. The fourth phase reviews records that just became visible to FDA, such as management reviews, internal audits, and supplier audits, which were previously exempt but now are regulatory evidence.
Key facts
- QMSR effective for seven months at time of episode recording
- Proposed rule released three and a half years before QMSR implementation
- Risk management process must run through product realization under ISO 13485 Clause 7.3, not just at design validation
- FDA compliance program organizes inspection around six QMS areas plus four FDA-specific requirements
- July 2024: Nikhil Mangali promoted to Vice President of Quality at Capstone Medical
People, companies and topics mentioned
More answers from this episode
- 0:54What are the top 5 FDA citations from QMSR audits according to real inspection data?
- 3:00Why is risk management the most cited QMSR compliance violation?
- 5:15What specific supplier control issues are FDA citing under QMSR?
- 14:20How should legacy medical devices with older DHF files approach QMSR compliance?
- 17:45What are the three layers of DHF to ISO 13485 mapping and what do most companies miss?